167 related articles for article (PubMed ID: 21532508)
1. Preoperative taxane-based chemotherapy and celecoxib for carcinoma of the esophagus and gastroesophageal junction: results of a phase 2 trial.
Altorki NK; Christos P; Port JL; Lee PC; Mirza F; Spinelli C; Keresztes R; Beneck D; Paul S; Stiles BM; Zhang Y; Schrump DS
J Thorac Oncol; 2011 Jun; 6(6):1121-7. PubMed ID: 21532508
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
3. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Komaki R; Putnam JB; Walsh G; Nesbitt J; Pisters PW; Lynch PM; Vaporciyan A; Smythe R; Lahoti S; Raijman I; Swisher S; Martin FD; Roth JA
Cancer; 2001 Jul; 92(2):279-86. PubMed ID: 11466680
[TBL] [Abstract][Full Text] [Related]
4. Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial.
Keresztes RS; Port JL; Pasmantier MW; Korst RJ; Altorki NK
J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1603-8. PubMed ID: 14666040
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
Altorki NK; Port JL; Zhang F; Golijanin D; Thaler HT; Duffield-Lillico AJ; Subbaramaiah K; Dannenberg AJ
Clin Cancer Res; 2005 Jun; 11(11):4191-7. PubMed ID: 15930356
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Altorki NK; Keresztes RS; Port JL; Libby DM; Korst RJ; Flieder DB; Ferrara CA; Yankelevitz DF; Subbaramaiah K; Pasmantier MW; Dannenberg AJ
J Clin Oncol; 2003 Jul; 21(14):2645-50. PubMed ID: 12860939
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Rodriguez CP; Adelstein DJ; Rice TW; Rybicki LA; Videtic GM; Saxton JP; Murthy SC; Mason DP; Ives DI
J Thorac Oncol; 2010 Feb; 5(2):229-35. PubMed ID: 20009775
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
Govindan R; McLeod H; Mantravadi P; Fineberg N; Helft P; Kesler K; Hanna N; Stoner C; Ansari R; Fox E
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):18-21. PubMed ID: 15685829
[TBL] [Abstract][Full Text] [Related]
9. Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Spizzo G; Öfner D; de Vries A; Lukas P; Steger G; Pluschnig U; Zacherl J; Widder J; Zabernigg A; Gastl G; Mühlmann G
Ann Surg Oncol; 2011 Mar; 18(3):677-83. PubMed ID: 21063792
[TBL] [Abstract][Full Text] [Related]
10. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
Ajani JA; Walsh G; Komaki R; Morris J; Swisher SG; Putnam JB; Lynch PM; Wu TT; Smythe R; Vaporciyan A; Faust J; Cohen DS; Nivers R; Roth JA
Cancer; 2004 Jun; 100(11):2347-54. PubMed ID: 15160337
[TBL] [Abstract][Full Text] [Related]
11. Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.
Lu B; Lu C; Sun Z; Qu C; Chen J; Hua Z; Tong R; Zhang J
J Int Med Res; 2019 May; 47(5):2207-2214. PubMed ID: 30991863
[TBL] [Abstract][Full Text] [Related]
12. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Gray JR; Thomas M; Sutton VM; Davis JL; Kalman LA; Shaffer DW; Yost K; Rinaldi DA; Hainsworth JD
Cancer J; 2003; 9(4):251-60. PubMed ID: 12967135
[TBL] [Abstract][Full Text] [Related]
13. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone.
Ancona E; Ruol A; Santi S; Merigliano S; Sileni VC; Koussis H; Zaninotto G; Bonavina L; Peracchia A
Cancer; 2001 Jun; 91(11):2165-74. PubMed ID: 11391598
[TBL] [Abstract][Full Text] [Related]
14. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Lustberg MB; Bekaii-Saab T; Young D; Otterson G; Burak W; Abbas A; McCracken-Bussa B; Lustberg ME; Villalona-Calero MA
J Thorac Oncol; 2010 May; 5(5):713-8. PubMed ID: 20354452
[TBL] [Abstract][Full Text] [Related]
15. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
Kleinberg L; Knisely JP; Heitmiller R; Zahurak M; Salem R; Burtness B; Heath EI; Forastiere AA
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):328-34. PubMed ID: 12738305
[TBL] [Abstract][Full Text] [Related]
16. Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival.
Darnton SJ; Archer VR; Stocken DD; Mulholland PJ; Casson AG; Ferry DR
J Clin Oncol; 2003 Nov; 21(21):4009-15. PubMed ID: 14581424
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Heath EI; Burtness BA; Heitmiller RF; Salem R; Kleinberg L; Knisely JP; Yang SC; Talamini MA; Kaufman HS; Canto MI; Topazian M; Wu TT; Olukayode K; Forastiere AA
J Clin Oncol; 2000 Feb; 18(4):868-76. PubMed ID: 10673530
[TBL] [Abstract][Full Text] [Related]
19. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Groen HJ; Sietsma H; Vincent A; Hochstenbag MM; van Putten JW; van den Berg A; Dalesio O; Biesma B; Smit HJ; Termeer A; Hiltermann TJ; van den Borne BE; Schramel FM
J Clin Oncol; 2011 Nov; 29(32):4320-6. PubMed ID: 21990410
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer.
Knox JJ; Wong R; Visbal AL; Horgan AM; Guindi M; Hornby J; Xu W; Ringash J; Keshavjee S; Chen E; Haider M; Darling G
Cancer; 2010 Sep; 116(17):4023-32. PubMed ID: 20533506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
